Roche launches the new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing

Roche-launches-the-new-cobas-e-801-module-helping-hospitals-meet-the-demand-for-increased-diagnostic-testing (1)

Ageing populations, increasing rates of chronic disease, and newly emergent diseases are having a major impact on healthcare services worldwidei,ii,iii. With ever-increasing financial pressures on these services, it is clear that the healthcare industry needs to prepare today to meet the challenges of tomorrow. Part of the answer is having the right infrastructure in place, with the capabilities to adapt to the needs of a changing world.

The cobas e 801 module is the newest member of the cobas 8000 modular analyzer series. It offers more than 100 immunoassays, across a wide range of disease areas. Up to four cobas e 801 modules can be configured in series, delivering up to 1’200 tests per hour across up to 192 reagent positions.

As diagnostic laboratories evolve to meet growing workloads in an increasingly challenging environment, the cobas e 801 module offers high value through its flexibility, which allows for the efficient use of existing resources such as space, infrastructure and personnel. The module is designed for maximum consolidation at a high throughput, continuous operation and, at the same time, it reduces the amount of waste generated, for more environmentally friendly testing.

The system allows for continuous loading of reagents and consumables and has a high uptime while requiring less hands-on time. The possible turn-around times for routine and emergency samples are the lowest available on the central laboratory market, with 18 minutes for routine and 9 minutes for emergency tests, for instance with cardiac markers.iv The small sample volumes required for testing are especially beneficial for critical patients, such as neonates and oncology patients. The cobas e 801 module uses the well-established Elecsys® technology.

The cobas e 801 module almost doubles the currently available immunochemistry testing capacity on the same footprint. The system only requires a low sample volume, offers an extensive assay menu and delivers fast, reliable and consistent patient results across systems. This benefits patients and healthcare professionals by providing the accurate and timely results needed to make the correct treatment decisions.

 

References

i. http://www.kingsfund.org.uk/time-to-think-differently/timeline
ii. http://www.pwc.com/gx/en/industries/healthcare/emerging-trends-pwc-healthcare/chronic-diseases.html
iii. http://kff.org/global-health-policy/fact-sheet/the-u-s-government-global-emerging-infectious-disease-preparedness-and-response/
iv. Package insert data. 2014